---
title: '2026ã€Šç§‘å­¸ã€‹ç ”ç©¶é•·å£½æ–°è«–ï¼šç•¶åŸºå› å½±éŸ¿å¾ 25% èºå‡è‡³ 55% ï¼Œå¦‚æœç¡¬é«”å¤©è³¦å·²å®šï¼Œä½ æ­£åœ¨éŒ¯èª¤åœ°è€—æç´°èƒå—ï¼Ÿ'
description: 'ã€ŒæŠ—è¡°è€çš„æœ¬è³ªï¼Œä¸æ˜¯ç‚ºäº†èº²é¿æ­»äº¡ï¼Œè€Œæ˜¯ç‚ºäº†ç¸®çŸ­èˆ‡ç–¾ç—…çºé¬¥çš„æ™‚é–“ã€‚ã€'
pubDate: 2026-02-12T13:49:27+08:00
---

_101_

æœ€è¿‘ã€Šç§‘å­¸ã€‹ï¼ˆScienceï¼‰æœŸåˆŠç™¼è¡¨äº†ä¸€é …ä»¤æ‰€æœ‰å¥èº«èˆ‡å¥åº·é£²é£Ÿæ„›å¥½è€…æ„Ÿåˆ°ã€Œå¿ƒæ¶¼ã€çš„ç ”ç©¶ï¼š

**é€™é …ç ”ç©¶æŒ‡å‡ºï¼Œåœ¨æ’é™¤äº†æ„å¤–èˆ‡å‚³æŸ“ç—…å¾Œï¼Œäººé¡ã€å…§åœ¨è¡°è€é€Ÿåº¦ã€çš„å·®ç•°ï¼Œæœ‰ 55% æ˜¯ç”±åŸºå› è¨­å®šçš„ã€‚**

**ä½ å¯ä»¥æƒ³åƒï¼Œæ¯å€‹äººå‡ºå» æ™‚çš„ç¡¬é«”è¨­å‚™ï¼ˆç´°èƒä¿®å¾©åŠ›ï¼‰æ•ˆèƒ½ä¸åŒï¼Œæœ‰äº›äººå¤©ç”Ÿå°±æ˜¯å·¥æ¥­ç´šä¼ºæœå™¨ï¼Œæœ‰äº›äººå‰‡æ˜¯å®¶ç”¨ç­†é›»ã€‚ã€**

ä¸ï¼Œé€™åè€Œè­‰æ˜äº†ç”Ÿæ´»æ–¹å¼çš„é‡è¦æ€§ã€‚

å…§å®¹ç›®éŒ„

Toggle

## **éºå‚³åŠ›çš„ã€Œçµ±è¨ˆé™·é˜±ã€â€”â€”ç‚ºä»€éº¼å®ƒä¸æ˜¯ç‰©ç†å¸¸æ•¸ï¼Ÿ**

é¦–å…ˆï¼Œæˆ‘å€‘è¦å°æ­£ä¸€å€‹æœ€å¸¸è¦‹çš„èªçŸ¥åå·®ï¼š**éºå‚³åŠ›ï¼ˆHeritability, h 2ï¼‰ä¸¦ä¸æ˜¯ä¸€ç¨®å‘½å®šè«–ã€‚**

åœ¨ç”Ÿç‰©å­¸ä¸­ï¼Œéºå‚³åŠ›æ˜¯ä¸€å€‹ã€Œçµ±è¨ˆé‡ã€ã€‚

å®ƒæè¿°çš„æ˜¯ï¼š**ã€Œåœ¨ä¸€å€‹ç‰¹å®šæ—ç¾¤ä¸­ï¼Œå€‹é«”é–“è¡¨ç¾å‹ï¼ˆå¦‚å£½å‘½ï¼‰çš„å·®ç•°ï¼Œæœ‰å¤šå°‘æ¯”ä¾‹å¯ä»¥æ­¸å› æ–¼åŸºå› å·®ç•°ï¼Ÿã€**

  * **å‹•æ…‹çš„éºå‚³åŠ›ï¼š** æƒ³åƒä½ åœ¨ä¸€å€‹æ¥µåº¦é£¢è’çš„åœ°å€ç ”ç©¶èº«é«˜ï¼Œéºå‚³åŠ›æœƒè®Šå¾—å¾ˆä½ï¼Œå› ç‚ºå¤§å®¶çš„æˆé•·éƒ½è¢«ã€Œç’°å¢ƒï¼ˆæ²’é£¯åƒï¼‰ã€é™åˆ¶ä½äº†ã€‚ä½†å¦‚æœå¤§å®¶ç‡Ÿé¤Šéƒ½å……è¶³ï¼Œèº«é«˜çš„å·®ç•°å°±æœƒä¸»è¦ä¾†è‡ªåŸºå› ï¼Œéºå‚³åŠ›éš¨ä¹‹é£†å‡ã€‚
  * **å£½å‘½çš„ç‰¹æ®Šæ€§ï¼š** å£½å‘½æ˜¯æ‰€æœ‰ç”Ÿç‰©ç‰¹å¾µä¸­æœ€é›£æ¸¬é‡çš„ï¼Œå› ç‚ºå®ƒå—ã€Œé‹æ°£ï¼ˆå¤–å› æ€§æ­»äº¡ï¼‰ã€å½±éŸ¿å¤ªå¤§ã€‚å¦‚æœä¸€å°åŸºå› å„ªè‰¯çš„é›™èƒèƒï¼Œå…¶ä¸­ä¸€äººåœ¨ 20 æ­²ä¸å¹¸æ­»æ–¼è»Šç¦ï¼Œå‚³çµ±çµ±è¨ˆå°±æœƒåˆ¤å®šã€ŒåŸºå› å°å£½å‘½å½±éŸ¿å¾ˆå°ã€ï¼Œé€™å°±æ˜¯æ•¸æ“šçš„ã€Œé›œè¨Šã€ã€‚

## **å¤–å› èˆ‡å…§å› çš„ç”Ÿæ­»åšå¼ˆâ€”â€” Gompertz æ¨¡å‹èˆ‡ m ex**

ç‚ºäº†ç²¾æº–åˆ†æï¼Œç§‘å­¸å®¶å¼•å…¥äº† **Gompertz-Makeham æ­»äº¡ç‡å®šå¾‹** ã€‚

æˆ‘å€‘å°‡ç¸½æ­»äº¡é¢¨éšª m(t) åˆ†è§£ç‚ºå…©å€‹æ ¸å¿ƒåˆ†é‡ï¼š

m(t) = mex \+ f(t; ğœƒ)

**å…§å› æ€§æ­»äº¡ï¼ˆIntrinsic Mortality, f(t; ğœƒ)ï¼‰ï¼š** é€™æ˜¯çœŸæ­£çš„ã€Œç”Ÿç‰©æ™‚é˜ã€ã€‚

éš¨è‘—å¹´é½¡å¢é•·ï¼Œç´°èƒä¿®å¾©å‡ºéŒ¯ã€ç·šç²’é«”åŠŸèƒ½è¡°é€€ã€è›‹ç™½è³ªæ‘ºç–ŠéŒ¯èª¤å †ç©ã€‚

é€™éƒ¨åˆ†å‘ˆç¾æŒ‡æ•¸å‹ä¸Šå‡ï¼Œä¹Ÿå°±æ˜¯æ‰€è¬‚çš„ **Gompertz æ–œç‡** ã€‚

**å¤–å› æ€§æ­»äº¡ï¼ˆExtrinsic Mortality, m exï¼‰ï¼š**é€™æ˜¯ä¸€é …èˆ‡å¹´é½¡å¹¾ä¹ç„¡é—œçš„èƒŒæ™¯é¢¨éšªã€‚

ç„¡è«–ä½ å¹¾æ­²ï¼Œè¢«éš•çŸ³æ‰“åˆ°ã€æ„ŸæŸ“æ–°å‹ç—…æ¯’ã€æˆ–é­é‡äº¤é€šäº‹æ•…çš„æ©Ÿç‡ç›¸å°ç©©å®šã€‚é€™éƒ¨åˆ†æ˜¯ã€Œç’°å¢ƒçš„å™ªéŸ³ã€ã€‚

## é›™èƒèƒç ”ç©¶çš„æ•¸å­¸æ¨¡å‹â€”â€”ç‚ºä»€éº¼æ˜¯ 55%ï¼Ÿ

ç ”ç©¶è€…ä½¿ç”¨äº†**çª„ç¾©éºå‚³åŠ›ï¼ˆNarrow-sense Heritability, h 2ï¼‰**ï¼Œé€™ä»£è¡¨ã€ŒåŠ æ€§éºå‚³è®Šç•°ã€çš„å æ¯”ã€‚

å…¬å¼å¦‚ä¸‹ï¼š

h2 â‰ˆ 2 * (rMZâ€“ rDZ)

  * **åŒåµé›™èƒèƒ (r MZ)ï¼š** åŸºå›  100% ç›¸åŒã€‚
  * **ç•°åµé›™èƒèƒ (r DZ)ï¼š** åŸºå› å¹³å‡ 50% ç›¸åŒã€‚

ç•¶ä½œè€…æ ¡æ­£äº†ã€Œç´å…¥é–€æª»ï¼ˆCutoff ageï¼‰ã€å¾Œç™¼ç¾ï¼Œå¦‚æœåªçœ‹ 15 æ­²ä»¥å¾Œçš„å­˜æ´»æ•¸æ“šï¼Œä¸¦å»é™¤ç’°å¢ƒå¹²æ“¾ï¼ŒåŒåµé›™èƒèƒçš„å£½å‘½ç›¸é—œæ€§é é«˜æ–¼ç•°åµã€‚

é€™èªªæ˜äº†ï¼š**ç•¶ç’°å¢ƒè®Šå¾—æ¥µç«¯å®‰å…¨ï¼ˆç¾ä»£ç¤¾æœƒï¼‰ï¼Œæˆ‘å€‘æ¯”æ‹¼çš„ç´”ç²¹å°±æ˜¯ç”Ÿç‰©æ€§çš„ã€ŒæŠ˜èˆŠé€Ÿç‡ã€ã€‚**

## **100 å¹´å‰çš„ã€Œé•·å£½å¹»è±¡ã€ï¼šç‚ºä»€éº¼æˆ‘å€‘æ›¾ä»¥ç‚ºç”Ÿæ´»èƒ½æ±ºå®šä¸€åˆ‡ï¼Ÿ**

â€‹å›é¡§ 1996 å¹´é‚£ä»½ç¶“å…¸çš„ã€Œä¸¹éº¥é›™èƒèƒç ”ç©¶ã€ï¼Œç§‘å­¸å®¶ç•¶æ™‚ä¿¡èª“æ—¦æ—¦åœ°å‘Šè¨´æˆ‘å€‘ï¼š**ã€ŒåŸºå› åªä½” 25%ï¼Œå‰©ä¸‹çš„ 80% æŒæ¡åœ¨ä½ çš„ç”Ÿæ´»æ–¹å¼ä¸­ã€‚ã€**

â€‹**ç‚ºä»€éº¼åŒç‚ºä¸¹éº¥é›™èƒèƒæ•¸æ“šï¼Œçµè«–å»å¤©å·®åœ°é ï¼Ÿ**

â€‹åŸå› åœ¨æ–¼ã€Œæ™‚ä»£èƒŒæ™¯ã€ã€‚

100 å¹´å‰çš„äººé¡ï¼Œä¸»è¦æ­»æ–¼ï¼š

  * â€‹å¤§è¦æ¨¡å‚³æŸ“ç—…ï¼ˆè‚ºçµæ ¸ã€é¼ ç–«ï¼‰
  * â€‹äºŒæˆ°å‰çš„é†«ç™‚åŒ±ä¹
  * â€‹é »ç¹çš„æ„å¤–èˆ‡ç‡Ÿé¤Šä¸è‰¯

â€‹åœ¨é‚£å€‹å¹´ä»£ï¼Œã€Œç’°å¢ƒï¼ˆé‹æ°£ï¼Œæˆ–æ˜¯èªªä½ å‡ºç”Ÿåœ¨å“ªè£¡ï¼‰ã€æ±ºå®šäº†ä½ èƒ½ä¸èƒ½æ´»é 50 æ­²ã€‚

ä¹Ÿå°±æ˜¯éå»çš„ç ”ç©¶ï¼ˆå¦‚ 1996 å¹´ä¸¹éº¥é›™èƒèƒç ”ç©¶ï¼‰ä½¿ç”¨çš„æ˜¯æ­·å²æ•¸æ“šï¼Œç•¶æ™‚çš„ mex æ¥µé«˜ã€‚

ç•¶èƒŒæ™¯å™ªéŸ³å¤ªå¤§æ™‚ï¼ŒåŸºå› çš„è¨Šè™Ÿæœƒè¢«ã€Œç¨€é‡‹ã€ã€‚

2026 å¹´é€™ç¯‡ç ”ç©¶é€é AI æ¨¡æ“¬æ ¡æº–ï¼Œå°‡ mex è¨­ç‚º 0ï¼Œé€²è¡Œã€Œåäº‹å¯¦æ¨ä¼°ï¼ˆCounterfactual Estimationï¼‰ã€ï¼Œé€™æ‰è®“è—åœ¨é›œè¨Šä¸‹çš„åŸºå› è¨Šè™Ÿï¼ˆ55%ï¼‰é¡¯ç¾å‡ºä¾†ã€‚

## **â€‹ é†«ç™‚é©å‘½çš„çœŸç›¸ï¼šæˆ‘å€‘åªæ˜¯è®“æ›´å¤šäººã€Œæ´»åˆ°ä¸Šé™ã€**

â€‹ã€Œæˆ°å¾ŒæŠ—ç”Ÿç´ çš„ç™¼ç¾èˆ‡å…¬å…±è¡›ç”Ÿç™¼é”ï¼ŒæŠ¹å»äº†å¤§é‡çš„ã€éš¨æ©Ÿæ­»äº¡é¢¨éšªã€ï¼ˆå¦‚æ„ŸæŸ“èˆ‡å‚³æŸ“ç—…ï¼‰ã€‚

ç•¶æˆ‘å€‘æ‰£é™¤æ‰é€™äº›é‹æ°£æˆåˆ†ï¼ŒçœŸç›¸æµ®å‡ºæ°´é¢ï¼šäººé¡ç”Ÿç‰©æ€§çš„è¡°è€é€Ÿç‡ï¼ˆGompertz æ–œç‡ï¼‰åœ¨ç™¾å¹´ä¾†å¹¾ä¹ç´‹çµ²ä¸å‹•ã€‚ã€**ã€‚**

â€‹ç¾ä»£äººä¸å†æ­»æ–¼æ„å¤–ï¼Œè€Œæ˜¯é›†é«”æ’ä¸Šäº†ã€Œå››å¤§æ…¢æ€§ç—…ã€çš„é«˜ç‰†ï¼š

  1. â€‹å¿ƒè¡€ç®¡ç–¾ç—…
  2. â€‹ç™Œç—‡
  3. â€‹ä»£è¬ç›¸é—œç–¾ç—…ï¼ˆå¦‚ï¼šç³–å°¿ç—…ï¼‰
  4. â€‹ç¥ç¶“é€€åŒ–ç–¾ç—…ï¼ˆå¦‚ï¼šå¤±æ™ºç—‡ï¼‰
  5. 

â€‹ç•¶ç’°å¢ƒè®Šå¾—æ¥µç«¯å®‰å…¨ï¼Œæ±ºå®šä½ ä½•æ™‚ã€Œæ’ç‰†ã€çš„ï¼Œå°±åªå‰©ä¸‹ä½ åŸºå› ä¸­è¨­å®šçš„ç´°èƒä¿®å¾©é€Ÿåº¦â€”â€”ä¹Ÿå°±æ˜¯æ‰€è¬‚çš„**æµ·å¼—é‡Œå…‹æ¥µé™ï¼ˆHayflick Limitï¼‰** ï¼š125 æ­²çš„ç´°èƒåˆ†è£‚å¤©èŠ±æ¿ã€‚

ç¾åœ¨æˆ‘å€‘æ´»åœ¨å®‰å…¨çš„ç’°å¢ƒï¼Œæ±ºå®šä½ ä½•æ™‚ã€æ’ä¸Šæ…¢æ€§ç—…é«˜ç‰†ã€çš„ï¼Œå°±æ˜¯ä½ é‚£ 55% çš„å¤©ç”Ÿä¿®å¾©åŠ›ã€‚

é€™ä»£è¡¨ï¼šä½ çš„ç”Ÿæ´»æ–¹å¼å¦‚æœä¸å¤ ç²¾æº–ï¼Œä½ æœƒæ¯”åˆ¥äººæ›´å¿«è€—ç›¡å¤©è³¦ã€‚ã€

## **Healthspanï¼ˆå¥åº·å£½å‘½ï¼‰æ¯” Lifespanï¼ˆæœ€å¤§å£½å‘½ï¼‰æ›´é‡è¦**

å¦‚æœç”Ÿå‘½å‘¨æœŸï¼ˆæœ€å¤§å£½å‘½ï¼‰å¾ˆé•·ä½†å¥åº·å£½å‘½å¾ˆçŸ­ï¼Œé‚£æ„å‘³è‘—å¾ˆå¤šå¹´éƒ½è¦ç”Ÿæ´»åœ¨ç–¾ç—…æˆ–æ®˜ç–¾ä¸­ã€‚

ä½†æ˜¯ç”Ÿå‘½å‘¨æœŸå¦‚æœèƒ½è·Ÿå¥åº·å£½å‘½é‡ç–Šï¼Œé‚£å°±æ„å‘³è‘—ç”Ÿå‘½å¤§éƒ¨åˆ†çš„æ™‚é–“éƒ½æ˜¯å¥åº·çš„ã€‚

åªå¯æƒœç¾åœ¨çš„é†«ç™‚æŠ€è¡“èˆ‡äººå€‘çš„é—œæ³¨åŠ›ï¼Œæœ€å¤šæŠŠç”Ÿå‘½å‘¨æœŸå»¶é•·ä¸€æ®µï¼Œè€Œå¥åº·å£½å‘½æœªèƒ½è·Ÿè‘—å¢åŠ ï¼ˆ**åœ–åº•ä¸‹è™›ç·šå¢åŠ éƒ¨åˆ†** ï¼‰ã€‚

### **æ•¸æ“šå°æ¯”ï¼šä½ æƒ³è¦å“ªä¸€ç¨®ã€Œæ™šå¹´ç‰ˆæœ¬ã€ï¼Ÿ**

çœŸæ­£çš„å‹è² å°±åœ¨æ–¼ï¼šä½ æ‰“ç®—èŠ±å¤šä¹…æ™‚é–“ã€Œç”Ÿç—…ã€ï¼Ÿ

åœ¨é†«å­¸ç•Œï¼Œé€™è¢«ç¨±ç‚ºã€Œå£“ç¸®ç™¼ç—…ç‡ã€çš„æˆ°çˆ­ã€‚

æˆ‘å€‘ä¾†çœ‹çœ‹é€™å…©å€‹æ•¸æ“šçš„æ®˜é…·å°æ¯”ï¼š

#### **ç‰ˆæœ¬ Aï¼šç¾ä»£é†«ç™‚çš„ã€Œå»¶å¾Œæ­»äº¡ã€**

å¥åº·å£½å‘½ï¼š 65 æ­²ï¼ˆé–‹å§‹å‡ºç¾ç¬¬ä¸€ç¨®æ…¢æ€§ç—…ï¼‰ã€‚

å¤±èƒ½/è—¥ç½å­æœŸï¼š 15 ~ 20 å¹´ã€‚

ç¾ç‹€ï¼š é›–ç„¶æ´»åˆ°äº† 85 æ­²ï¼Œä½†æ™šå¹´æœ‰ 1/4 çš„æ™‚é–“æ˜¯åœ¨è¨ºæ‰€ã€ç—…æ¦»æˆ–ä¾è³´è—¥ç‰©ä¸­åº¦éã€‚

é€™å°±æ˜¯ç‚ºä»€éº¼å¤§å®¶èªªã€Œæ´»å¾—ä¹…ä¸å¦‚æ´»å¾—å¥½ã€ã€‚

#### **ç‰ˆæœ¬ Bï¼šæŠ—è¡°è€ä»‹å…¥çš„ã€Œå£“ç¸®ç™¼ç—…ç‡ã€**

å¥åº·å£½å‘½ï¼š 85 æ­²ï¼ˆé€éä»‹å…¥ï¼Œè®“ç–¾ç—…å»¶å¾Œ 20 å¹´ç™¼ç”Ÿï¼‰ã€‚

å¤±èƒ½/è¡°å¼±æœŸï¼š 2 ~ 5 å¹´ã€‚

ç›®æ¨™ï¼š åŒæ¨£æ´»åˆ° 90 æ­²ï¼Œä½†ä½ ç¶­æŒç”Ÿç†å·”å³°çš„æ™‚é–“æ‹‰é•·äº†ï¼Œæœ€å¾Œçš„ã€Œä¸‹å¡è·¯ã€è¢«å£“ç¸®åˆ°æ¥µçŸ­ã€‚

## **çœŸæ­£çš„å•é¡Œæ‡‰è©²æ˜¯æˆ‘å€‘èƒ½å¥åº·åœ°æ´»å¤šä¹…**

ã€ŒæŠ—è¡°è€çš„æœ¬è³ªï¼Œä¸æ˜¯ç‚ºäº†èº²é¿æ­»äº¡ï¼Œè€Œæ˜¯ç‚ºäº†ç¸®çŸ­èˆ‡ç–¾ç—…çºé¬¥çš„æ™‚é–“ã€‚ã€

ç•¶ä½ ã€Œæ„Ÿè¦ºè€äº†ã€æ‰é–‹å§‹ï¼Œé‚£ä¸å«ç®¡ç†ï¼Œé‚£å«ä¿®è£œã€‚

ã€Œæˆ‘å€‘ä¸èƒ½æ”¹è®Šæµ·å¼—é‡Œå…‹æ¥µé™çš„çµ‚é»ï¼Œä½†æˆ‘å€‘å¯ä»¥æ”¹è®ŠæŠµé”çµ‚é»å‰çš„è·¯å¾‘ã€‚ã€

â€‹â€‹é€™å°±æ˜¯ç‚ºä»€éº¼æˆ‘å€‘èªªï¼š**æŠ—è¡°è€è¦è¶æ—©** ã€‚

## **AI é†«ç™‚é©å‘½â€”â€”å¾ã€Œè‚‰çœ¼å°èˆªã€åˆ°ã€Œå…¨è‡ªå‹•ç”Ÿå‘½é›·é”ã€**

â€‹ç‚ºä»€éº¼æˆ‘å€‘éœ€è¦ AIï¼Ÿ

å› ç‚ºç”Ÿç‰©å­¸å¤ªè¤‡é›œäº†ï¼Œéå»æˆ‘å€‘å»é†«é™¢ï¼Œçœ‹çš„æ˜¯ã€Œ**éœæ…‹å ±å‘Š** ã€ã€‚

è¡€ç³– 110ï¼Ÿé†«ç”Ÿèªªå†è§€å¯Ÿã€‚

è¡€å£“ 140ï¼Ÿå¯èƒ½æ˜¯æœ‰é»ç·Šå¼µã€‚

é€™ç¨®å‚³çµ±é†«å­¸æ¨¡å¼å«ä½œã€Œ**åæ‡‰å¼é†«ç™‚** ï¼ˆReactive Medicineï¼‰ã€ï¼Œä¹Ÿå°±æ˜¯ç«ç‡’èµ·ä¾†äº†æ‰å»æ»…ç«ã€‚

ä½†ç”Ÿç‰©è€åŒ–æ˜¯ä¸€å€‹**éç·šæ€§ã€å¤šç¶­åº¦** çš„éç¨‹ã€‚

ä½ çš„ç–²å‹æ„Ÿå¯èƒ½ä¾†è‡ªç·šç²’é«”åŠŸèƒ½ä¸‹é™ã€å¯èƒ½ä¾†è‡ªçš®è³ªé†‡ï¼ˆå£“åŠ›è·çˆ¾è’™ï¼‰éé«˜ï¼Œä¹Ÿå¯èƒ½ä¾†è‡ªå¾®ç´°çš„æ…¢æ€§ç™¼ç‚ã€‚

äººé¡å¤§è…¦ç„¡æ³•åŒæ™‚è¨ˆç®—ä¸Šç™¾ç¨®æ•¸æ“šçš„é—œè¯ï¼Œé€™å°±æ˜¯ AI çš„å¼·é …ï¼š**å®ƒèƒ½å¾å¾®å°çš„æ•¸æ“šæ³¢å‹•ä¸­ï¼Œé æ¸¬æœªä¾†çš„ç½é›£ã€‚**

## **ç©¿æˆ´å¼è£ç½®â€”â€”ä½ éš¨èº«çš„ 24 å°æ™‚ç”Ÿç‰©å¯¦é©—å®¤ï¼Œåœ¨å®¶å°±èƒ½æŒæ¡çš„ç§‘å­¸**

å¾ˆå¤šäººæˆ´ Apple Watch æˆ– Garmin åªæ˜¯ç‚ºäº†çœ‹æ­¥æ•¸æˆ–æ”¶è¨Šæ¯ï¼Œä½†åœ¨ç”Ÿç‰©å­¸å®¶çœ¼ä¸­ï¼Œã€Œç©¿æˆ´å¼è£ç½®ã€å°±æ˜¯ä½ èº«é«”çš„é»‘ç›’å­ç´€éŒ„å™¨ã€‚

é€™äº›è£ç½®èƒŒå¾Œçš„ AI æ¼”ç®—æ³•ï¼Œå…¶å¯¦æ­£åœ¨å¹«ä½ ç›£æ¸¬é‚£ã€Œ45% çš„å¾Œå¤©ä¸»å°æ¬Šã€ã€‚

### **é€£çºŒè¡€ç³–ç›£æ¸¬ï¼ˆCGMï¼‰èˆ‡ä»£è¬éˆæ´»æ€§ï¼š** å¾ˆå¤š 40 æ­²ä»¥ä¸Šçš„ä¸Šç­æ—ä¸‹åˆæœƒç´¯ï¼Œæ˜¯å› ç‚ºã€Œè¡€ç³–éå±±è»Šã€ã€‚

  * **AI çš„è§’è‰²ï¼š** ç¾åœ¨çš„ AI æ¼”ç®—æ³•ï¼ˆå¦‚æ­è¼‰åœ¨å„é¡å¥åº· App ä¸Šçš„æ¨¡å‹ï¼‰ä¸åªæ˜¯çœ‹è¡€ç³–æ•¸å­—ï¼Œå®ƒèƒ½åˆ†æä½ çš„ã€Œè¡€ç³–è®Šç•°æ€§ï¼ˆGlycemic Variabilityï¼‰ã€ã€‚
  * **è§£é‡‹** ï¼šå¦‚æœä½ çš„è¡€ç³–åƒå¿ƒé›»åœ–ä¸€æ¨£åŠ‡çƒˆè·³å‹•ï¼Œä½ çš„ç´°èƒå°±åœ¨ä¸æ–·é­å—ã€Œæ°§åŒ–å£“åŠ›ï¼ˆOxidative Stressï¼‰ã€çš„è½Ÿç‚¸ã€‚AI èƒ½å‘Šè¨´ä½ ï¼š**ã€Œå°ä½ é€™ç¨®é«”è³ªä¾†èªªï¼Œä¸­åˆé‚£ç¢—ç‚¸é†¬éºµæ¯”çå¥¶æ›´å‚·è¡€ç®¡ã€‚ã€** é€™å°±æ˜¯ç²¾æº–ç®¡ç†ã€‚

### **å¿ƒç‡è®Šç•°æ€§ï¼ˆHRVï¼‰èˆ‡è‡ªå¾‹ç¥ç¶“éŸŒæ€§ï¼š** HRV æ˜¯åæ˜ è‡ªå¾‹ç¥ç¶“ç³»çµ±ï¼ˆANSï¼‰å¹³è¡¡ç‹€æ…‹çš„æœ€ä½³æ¨™è¨˜ã€‚

  * **ç”Ÿç‰©å­¸è§£é‡‹ï¼š** HRV ä»£è¡¨å¿ƒè·³èˆ‡å¿ƒè·³ä¹‹é–“å¾®å°é–“éš”çš„è®ŠåŒ–ã€‚æ•¸å€¼è¶Šé«˜ï¼Œä»£è¡¨ä½ çš„èº«é«”éŸŒæ€§è¶Šå¥½ï¼Œèƒ½éš¨æ™‚æ‡‰å°å£“åŠ›ã€‚
  * **AI çš„åƒ¹å€¼ï¼š** AI èƒ½éæ¿¾æ‰ç’°å¢ƒé›œè¨Šï¼Œåˆ¤æ–·ä½ ä»Šå¤©çš„ç–²å‹æ˜¯ã€Œç”Ÿç†æ€§è€—æã€é‚„æ˜¯ã€Œå¿ƒç†æ€§å£“åŠ›ã€ã€‚å®ƒæœƒåœ¨ä½ çš„é«”åŠ›é€æ”¯å‰ 24 å°æ™‚ç™¼å‡ºè­¦å‘Šï¼Œæé†’ä½ ä»Šæ™šå¿…é ˆå¼·åˆ¶ä¼‘æ¯ï¼Œé˜²æ­¢ç´°èƒé€²å…¥ä¸å¯é€†çš„æå‚·æœŸã€‚

### ****å¿ƒç‡è®Šç•°æ€§ï¼ˆHRVï¼‰** èˆ‡ç¡çœ æ¶æ§‹ï¼š** ç‚ºä»€éº¼ä½ æ˜æ˜ç¡äº† 8 å°æ™‚ï¼Œéš”å¤©é–‹æœƒé‚„æ˜¯æƒ³æ‰“çŒç¡ï¼Ÿ

  * **ç”Ÿç‰©å­¸è§£é‡‹ï¼š** ç¡çœ ä¸ç­‰æ–¼ä¿®å¾©ã€‚å¦‚æœä½ çš„ç©¿æˆ´è£ç½®é¡¯ç¤ºã€Œæ·±å±¤ç¡çœ ï¼ˆDeep Sleepï¼‰ã€èˆ‡ã€Œå¿«é€Ÿå‹•çœ¼æœŸï¼ˆREMï¼‰ã€æ¯”ä¾‹å¤±è¡¡ï¼Œä»£è¡¨ä½ çš„å¤§è…¦æ¸…é“å¤«ç³»çµ±ï¼ˆGlymphatic Systemï¼‰æ˜¨æ™šæ ¹æœ¬æ²’ä¸Šç­ï¼Œç„¡æ³•æ¸…é™¤ä»£è¬å»¢ç‰©ï¼ˆå¦‚ Beta-é¡æ¾±ç²‰è›‹ç™½ï¼‰ã€‚
  * **AI çš„ç²¾æº–ä»‹å…¥ï¼š** AI æ¼”ç®—æ³•æœƒæ•´åˆä½ çš„å¿ƒç‡è®Šç•°æ€§ï¼ˆHRVï¼‰èˆ‡ç¡çœ æ›²ç·šã€‚ç•¶ä½ çœ‹åˆ°ä»Šæ—¥ã€Œèº«é«”èƒ½é‡ï¼ˆBody Batteryï¼‰ã€åªæœ‰ 30 åˆ†æ™‚ï¼Œé€™ä¸æ˜¯å«ä½ å·æ‡¶ï¼Œè€Œæ˜¯è­¦å‘Šä½ ï¼š**ä»Šæ—¥ä½ çš„ç´°èƒä¿®å¾©åŠ›è™•æ–¼ä½é»ï¼Œé«˜å¼·åº¦çš„å·¥ä½œå£“åŠ›æœƒé€ æˆé›™å€çš„æ°§åŒ–æå‚·ã€‚**

### **æœ€å¤§æ”æ°§é‡**ï¼ˆ** VO2 Max **ï¼‰** æ˜¯é•·å£½çš„ã€Œç¡¬æŒ‡æ¨™**ã€ï¼šé€™åœ¨ç”Ÿç‰©å­¸ä¸Šä»£è¡¨ä½ å¿ƒè‚ºè€åŠ›èˆ‡ç·šç²’é«”åŠŸèƒ½çš„ç¶œåˆè¡¨ç¾ã€‚

  * **æ•¸æ“šè¤‡åˆ©ï¼š** ç ”ç©¶é¡¯ç¤ºï¼ŒVO2 Max æ¯æå‡ä¸€å€‹ç­‰ç´šï¼Œå…¨å› æ­»äº¡é¢¨éšªæœƒä¸‹é™ç´„ 15-20%ã€‚é€™æ¯”ä»»ä½•æ˜‚è²´çš„è£œå“éƒ½æœ‰æ„Ÿã€‚
  * **AI çš„è§’è‰²ï¼š** AI æœƒè¿½è¹¤ä½ é•·æœŸçš„æ”æ°§é‡è®ŠåŒ–ã€‚å¦‚æœä½ é€™åŠå¹´çš„ VO2 Max æŒçºŒä¸‹é™ï¼ŒAI æœƒåœ¨ç–¾ç—…ç™¼ç”Ÿå‰å¹¾å¹´å°±ç™¼å‡ºæ©™è‰²é è­¦ï¼Œæé†’ä½ ã€Œå¿ƒè¡€ç®¡çš„æŠ˜èˆŠé€Ÿåº¦ã€å·²ç¶“è¶…éäº†åŸºå› é è¨­çš„ 55% å®‰å…¨å€ã€‚

### **AI è¡¨è§€éºå‚³é˜ï¼ˆEpigenetic Clocksï¼‰ï¼š** é€™æ˜¯ç›®å‰æœ€é ‚å°–çš„æŠ—è¡°è€æŠ€è¡“ã€‚

é€éæª¢æ¸¬ DNA ä¸Šçš„ã€Œç”²åŸºåŒ–æ¨™è¨˜ã€ï¼ŒAI å¯ä»¥è¨ˆç®—å‡ºä½ çš„ã€ŒçœŸå¯¦ç”Ÿç‰©å¹´é½¡ã€ã€‚

  * **æ‡‰ç”¨å ´æ™¯ï¼š** ä»¥å‰æˆ‘å€‘è¦èŠ±åå¹´æ‰çŸ¥é“æŸç¨®é¤Šç”Ÿæ³•æœ‰æ²’æœ‰æ•ˆï¼Œç¾åœ¨é€é AI è¿½è¹¤è¡¨è§€éºå‚³æ¨™è¨˜ï¼Œä¸‰å€‹æœˆå°±èƒ½çœ‹åˆ°ä½ çš„ç´°èƒä¿®å¾©é€Ÿåº¦æ˜¯å¦æå‡ã€‚
  * **æ·±åº¦åˆ†æï¼š** ä½ å¯èƒ½ 45 æ­²ï¼Œä½† AI åˆ†æé¡¯ç¤ºä½ çš„è¡€ç®¡å¹´é½¡å·²ç¶“ 55 æ­²ã€‚é€™å¤šå‡ºä¾†çš„ 10 æ­²ï¼Œå°±æ˜¯é‚£ 55% åŸºå› å„ªå‹¢è¢«ä½ æ®éœæ‰çš„è­‰æ“šã€‚

**â€‹æœ‰äº†éš¨èº«é›·é”ï¼Œæˆ‘å€‘ä¸å†å®³æ€•å…©èˆ¹ç›¸æ’ï¼Œæ›´ä¸å†å®³æ€•åœ¨åŸºå› çš„å®¿å‘½è£¡è¿·èˆªã€‚**

## **é€£ Open AI ä¹Ÿåƒä¸Šä¸€è…³**

Open AI å³å°‡æ¨å‡ºã€ŒChatGPT å¥åº·ã€ï¼Œé€™æ˜¯ä¸€å€‹å°ˆç‚ºå¥åº·æ‰“é€ çš„ç¨ç«‹é«”é©—ï¼Œèƒ½å¤ å®‰å…¨åœ°æ•´åˆä½ çš„å¥åº·è³‡è¨Šèˆ‡ ChatGPT çš„æ™ºæ…§ï¼Œå”åŠ©ä½ åœ¨é¢å°å¥åº·ç›¸é—œè­°é¡Œæ™‚ï¼Œæ„Ÿåˆ°æ›´æœ‰è³‡è¨ŠåŸºç¤ã€æ›´å……åˆ†æº–å‚™ï¼Œä¹Ÿæ›´æœ‰ä¿¡å¿ƒã€‚

è€Œä¸”æ“šå ±å°‡æ–¼ä»Šå¹´ 2026 å¹´ä¸‹åŠå¹´ç™¼å¸ƒé¦–æ¬¾ç¡¬é«”è¨­å‚™ï¼Œç”¢å“ä»£è™Ÿç‚ºã€ŒGumdropã€ï¼Œç”¢å“å‹æ…‹å¯èƒ½æœƒæ˜¯ç„¡è¢å¹•çš„å¯ç©¿æˆ´è¨­å‚™ï¼Œå¯èƒ½ç‚ºèƒ¸é‡æˆ–æ˜¯è€³æ©Ÿå½¢å¼ã€‚

## **ç‚ºä»€éº¼ä¸èƒ½ç­‰è€äº†å†ä¾†è™•ç†ï¼Ÿé€™æ˜¯ä¸€å€‹æ•¸å­¸å•é¡Œ**

èº«ç‚ºå¹´è–ªç™¾è¬ä»¥ä¸Šçš„ç²¾è‹±ï¼Œä½ ä¸€å®šæ‡‚ã€Œè¤‡åˆ©ã€çš„åŠ›é‡ã€‚

ä½†åœ¨ç”Ÿç‰©å­¸è£¡ï¼Œ**ã€Œæå®³ã€ä¹Ÿæ˜¯æœ‰è¤‡åˆ©çš„ã€‚**

### **ç™¼ç‚ï¼šéœæ‚„æ‚„çš„å­˜æ¬¾ç›œè³Š**

æ…¢æ€§ç™¼ç‚ï¼ˆInflammagingï¼‰åœ¨åˆæœŸæ˜¯æ„Ÿè¦ºä¸åˆ°ç—›çš„ã€‚

å®ƒå¯èƒ½åªæ˜¯ä½ è¡€æ¶²ä¸­é«˜æ• C-åæ‡‰è›‹ç™½ï¼ˆhs-CRPï¼‰çš„å¾®å¹…ä¸Šå‡ã€‚

åªæ˜¯æœƒè¦ºå¾—æ¯”è¼ƒç´¯ï¼Œå—å‚·å›å¾©æ¯”è¼ƒæ…¢ã€‚

  * **ç”Ÿç‰©å­¸æ©Ÿåˆ¶ï¼š** é€™äº›ç™¼ç‚å› å­æœƒåƒé½è·¡ä¸€æ¨£ï¼Œæ…¢æ…¢è…è•ä½ çš„è¡€ç®¡å£èˆ‡ç¥ç¶“çªè§¸ã€‚
  * **AI çš„é é˜²é‚è¼¯ï¼š** AI é†«ç™‚ç³»çµ±èƒ½æ•´åˆä½ éå»äº”å¹´çš„é«”æª¢æ•¸æ“šï¼Œç•«å‡ºä¸€æ¢è¶¨å‹¢ç·šã€‚ç•¶è¶¨å‹¢ç·šæ–œç‡ç•°å¸¸æ™‚ï¼Œå®ƒæœƒå‘Šè¨´ä½ ï¼šã€Œå¦‚æœä¸ä»‹å…¥ï¼Œä½ åœ¨ 12 å¹´å¾Œæ‚£ä¸Šé˜¿èŒ²æµ·é»˜ç—‡çš„æ©Ÿç‡å°‡æå‡ 300%ã€‚ã€

**å¹³å¸¸å›ºå®šæ™‚é–“çš„æ¸¬é‡è¡€å£“ã€è¡€è„‚ã€è¡€ç³–ï¼Œç¶­æŒèº«é«”çš„æ†å®šï¼›é–‹å§‹è¦è¶…æ¨™çš„æ™‚å€™å°±è¦æ³¨æ„ï¼Œä¸è¦éƒ½è®Šç´…å­—æ™‚å€™æ‰é–‹å§‹é—œå¿ƒã€‚**

**å¦å¤–å®šæœŸçš„å¥åº·æª¢æŸ¥æ˜¯é‡è¦çš„ï¼Œå¹´ç´€åˆ°äº†å°±ä¸è¦éµé½’ï¼Œè©²å»åšçš„æª¢æŸ¥å°±å»åšï¼Œå°¤å…¶æ˜¯å¤§è…¸ç›´è…¸é¡ã€èƒƒé¡ã€èƒ¸è…” X å…‰æ”å½±ã€ä¹³æˆ¿ X å…‰æ”å½±ã€å­å®®æŠ¹ç‰‡æª¢æŸ¥ç­‰ç­‰ï¼Œæ—©æœŸç™¼ç¾æ—©æœŸæ²»ç™‚ã€‚**

### **æ’åˆ°ã€Œå¥‡é»ã€åˆ°ä¾†ï¼šå¥åº·æœ¬é‡‘çš„é‡è¦æ€§**

æˆ‘å€‘åœ¨ 2026 å¹´è«‡é€™äº›ï¼Œæ˜¯å› ç‚ºé†«ç™‚æŠ€è¡“æ­£åœ¨ç™¼ç”Ÿ**æŒ‡æ•¸å‹çˆ†ç‚¸** ã€‚

  * **æ ¸å¿ƒè§€å¿µï¼š** ä½ çš„ä»»å‹™ä¸æ˜¯ç¾åœ¨å°±æ´»åˆ° 150 æ­²ï¼Œè€Œæ˜¯åˆ©ç”¨ AI ç›£æ¸¬ï¼Œç¢ºä¿ä½ çš„ã€Œç”Ÿç‰©å¹´é½¡ã€**å¢é•·é€Ÿåº¦æ…¢æ–¼** ã€Œæ—¥æ›†å¹´é½¡ã€ã€‚
  * **æŠ•è³‡æ¯”å–»ï¼š** åªè¦ä½ ç¾åœ¨èƒ½ä¿ä½ã€Œå¥åº·æœ¬é‡‘ã€ï¼Œä¸è®“æ…¢æ€§ç—…æå‰å ±åˆ°ï¼Œä½ å°±æœ‰æ©Ÿæœƒæ’åˆ° 2030 æˆ– 2035 å¹´é‚£å ´çœŸæ­£çš„ç´ç±³æ©Ÿå™¨äººæˆ–åŸºå› å‰ªè¼¯é©å‘½ã€‚

## **çµèª åˆ¥å†è¿·ä¿¡ã€Œé †å…¶è‡ªç„¶ã€**

åœ¨ 2026 å¹´çš„ä»Šå¤©ï¼Œæˆ‘å€‘æ“æœ‰çš„ AI æ•¸æ“šèˆ‡æŠ—è¡°è€ç§‘å­¸ï¼Œæ˜¯ç‚ºäº†è®“æˆ‘å€‘ä¸»å‹•å¥ªå›é‚£ 50% çš„æ§åˆ¶æ¬Šã€‚

ç•¶æˆ‘å€‘çŸ¥é“åŸºå› å äº† 55%ï¼Œæˆ‘å€‘å°±è©²æ›´æœ‰ç›®æ¨™åœ°å»å„ªåŒ–å‰©ä¸‹çš„ 45%ã€‚

å°æ–¼æ¯å¤©ä¸‹åˆæ„Ÿåˆ°ç–²æ†Šã€å·¥ä½œå£“åŠ›å·¨å¤§çš„ç™¾è¬å¹´è–ªæ—ç¾¤ä¾†èªªï¼Œä½ çš„ã€Œç¡¬é«”ã€å¯èƒ½æ­£åœ¨é«˜è² è¼‰é‹ä½œï¼Œå¦‚æœä¸é€éç²¾æº–çš„ä»‹å…¥ï¼ˆä»‹å…¥ç·šç²’é«”ã€ç®¡ç†è¡€ç³–éœ‡ç›ªï¼‰ï¼Œä½ å°±æ˜¯åœ¨åŠ é€Ÿæ¶ˆè€—é‚£ 55% çš„å¤©è³¦æœ¬é‡‘ï¼ˆæä¸å¥½ä½ æœ¬é‡‘å°±å¾ˆå°‘ï¼Œé‚„æƒ³åšä¸€æ¬¡å¤§çš„ï¼ŒçœŸè¦ä¸å¾—ï¼‰ã€‚  
  
â€‹**é•·å£½æ˜¯åŸºå› æ±ºå®šçš„ï¼Œä½†ã€Œå„ªé›…åœ°é•·å£½ã€ï¼Œæ˜¯ä½ æ±ºå®šçš„ã€‚**

åƒè€ƒè³‡æ–™ï¼š  
01\. L HAYFLICK, P S MOORHEAD, 1961.[The serial cultivation of human diploid cell strains.](https://pubmed.ncbi.nlm.nih.gov/13905658/)  _Exp Cell Res._ 25:585-621.  
02\. J F Fries, 1980. [Aging, natural death, and the compression of morbidity.](https://pubmed.ncbi.nlm.nih.gov/7383070/)  _N Engl J Med._ 303(3):130-5.  
03\. M McGue, J W Vaupel, N Holm, B Harvald, 1993. [Longevity is moderately heritable in a sample of Danish twins born 1870-1880.](https://pubmed.ncbi.nlm.nih.gov/8227991/) _J Gerontol._ 48(6):B237-44.  
04\. A M Herskind, M McGue, N V Holm, T I SÃ¸rensen, B Harvald, J W Vaupel, 1996. [The heritability of human longevity: a population-based study of 2872 Danish twin pairs born 1870-1900.](https://pubmed.ncbi.nlm.nih.gov/8786073/)  _Hum Genet._ 97(3):319-23.  
05\. Joris Deelen, Marian Beekman, Hae-Won Uh, Quinta Helmer, Maris Kuningas, Lene Christiansen, Dennis Kremer, Ruud van der Breggen, H Eka D Suchiman, Nico Lakenberg, Erik B van den Akker, Willemijn M Passtoors, Henning Tiemeier, Diana van Heemst, Anton J de Craen, Fernando Rivadeneira, Eco J de Geus, Markus Perola, Frans J van der Ouderaa, David A Gunn, Dorret I Boomsma, AndrÃ© G Uitterlinden, Kaare Christensen, Cornelia M van Duijn, Bastiaan T Heijmans, Jeanine J Houwing-Duistermaat, Rudi G J Westendorp, P Eline Slagboom, 2011. [Genome-wide association study identifies a single major locus contributing to survival into old age; the APOE locus revisited. ](https://pubmed.ncbi.nlm.nih.gov/21418511/)_Aging Cell._ 10(4):686-98.  
06\. Paola Sebastiani, Nadia Solovieff, Andrew T Dewan, Kyle M Walsh, Annibale Puca, Stephen W Hartley, Efthymia Melista, Stacy Andersen, Daniel A Dworkis, Jemma B Wilk, Richard H Myers, Martin H Steinberg, Monty Montano, Clinton T Baldwin, Josephine Hoh, Thomas T Perls, 2012. [Genetic signatures of exceptional longevity in humans.](https://pubmed.ncbi.nlm.nih.gov/22279548/) _PLoS One._ 2012;7(1):e29848.  
07\. Eileen M Crimmins, 2015.[Lifespan and Healthspan: Past, Present, and Promise](https://pubmed.ncbi.nlm.nih.gov/26561272/). _Gerontologist._ 55(6):901â€“911.  
08\. Xiao Dong, Brandon Milholland, Jan Vijg, 2016. [Evidence for a limit to human lifespan.](https://pubmed.ncbi.nlm.nih.gov/27706136/)  _Nature._ 538(7624):257-259.  
09\. Jan Vijg, Eric Le Bourg , 2017. [Aging and the Inevitable Limit to Human Life Span](https://pubmed.ncbi.nlm.nih.gov/28511176/).  _Gerontology._ 63(5):432-434.  
10\. Elie Dolgin, 2018. [Thereâ€™s no limit to longevity, says study that revives human lifespan debate. ](https://pubmed.ncbi.nlm.nih.gov/29968831/) _Nature._ 559(7712):14-15.  
11\. Timothy V Pyrkov, Konstantin Avchaciov, Andrei E Tarkhov, Leonid I Menshikov, Andrei V Gudkov, Peter O Fedichev, 2021. [Longitudinal analysis of blood markers reveals progressive loss of resilience and predicts human lifespan limit.](https://pubmed.ncbi.nlm.nih.gov/34035236/) _Nat Commun ._ 12(1):2765.  
12\. Armin Garmany, Satsuki Yamada, Andre Terzic, 2021. [Longevity leap: mind the healthspan gap.](https://pubmed.ncbi.nlm.nih.gov/34556664/) _NPJ Regen Med._ 6(1):57.  
S Jay Olshansky, Bradley J Willcox, Lloyd Demetrius, Hiram BeltrÃ¡n-SÃ¡nchez, 2024. [Implausibility of radical life extension in humans in the twenty-first century.](https://www.nature.com/articles/s43587-024-00702-3) _Nat Aging._ 4(11):1635-1642.  
11\. Yifan Yang, Avi Mayo, Tomer Levy, Naveh Raz, Ben Shenhar, Daniel F Jarosz, Uri Alon, 2025. [Compression of morbidity by interventions that steepen the survival curve.](https://pubmed.ncbi.nlm.nih.gov/40199852/)  _Nat Commun._ 16(1):3340.  
12\. Armin Garmany, Andre Terzic, 2025. [Healthspan-lifespan gap differs in magnitude and disease contribution across world regions. ](https://pubmed.ncbi.nlm.nih.gov/40890374/)_Commun Med (Lond)._ 5(1):381.  
13\. James Mitchell Crow, 2025. [Could humans live to 150? Why some researchers think weâ€™re on the cusp of a major longevity breakthrough.](https://pubmed.ncbi.nlm.nih.gov/41224985/) _Nature._ 647(8089):S2-S5.  
14\. Ben Shenhar, Glen Pridham, ThaÃ­s Lopes De Oliveira, Yifan Yang, Naveh Raz, Joris Deelen, View ORCID ProfileSara HÃ¤gg, Uri Alon, 2026. [Heritability of intrinsic human life span is about 50% when confounding factors are addressed.](https://pubmed.ncbi.nlm.nih.gov/41610249/) _Science._ 391(6784):504-510.  
15\. Mateus V. de Castro, Monize V.R. Silva, JoÃ£o Paulo L.F. Guilherme, Mayana Zatz, 2026. [Insights from Brazilian supercentenarians.](https://genomicpress.kglmeridian.com/view/journals/genpsych/2/1/article-p18.xml) _Genomic Psychiatry._ 2(1):18â€“20.  
16\. Peter Attia/[Outlive I+II: The Science and Art of Longevity](https://www.books.com.tw/products/0011001532?sloc=main)

> [ç§‘å­¸æ–°ç™¼ç¾ï¼äººé¡èº«é«”è¡°è€å¾å¹¾æ­²é–‹å§‹ï¼Ÿäººé¡å£½å‘½æœ‰æœ€çµ‚æ•¸å­—å—ï¼Ÿ](https://agelocked.com/%e7%a7%91%e5%ad%b8%e6%96%b0%e7%99%bc%e7%8f%be%ef%bc%81%e4%ba%ba%e9%a1%9e%e8%ba%ab%e9%ab%94%e8%a1%b0%e8%80%81%e5%be%9e%e5%b9%be%e6%ad%b2%e9%96%8b%e5%a7%8b%ef%bc%9f%e4%ba%ba%e9%a1%9e%e5%a3%bd%e5%91%bd/)

ğŸ‘‡ğŸ‘‡ğŸ‘‡ğŸ‘‡  

[ã€Œèè‹± ã€çš„å›èƒ½è§£æ–¹](https://lin.ee/jgugMvX)